✦ LIBER ✦

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis

✍ Scribed by Robert E. Bristow; Antonio Santillan; Ritu Salani; Teresa P. Diaz-Montes; Robert L. Giuntoli II; Benjamin C. Meisner; Deborah K. Armstrong; Kevin D. Frick

Book ID: 113961157
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 369 KB
Volume: 106
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.05.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intraperitoneal cisplatin therapy in ova

Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel

✍ Robert F. Ozols; Michael A. Bookman; Andreas du Bois; Jacobus Pfisterer; Alexand 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 204 KB

Carboplatin and Paclitaxel versus Cispla

Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

✍ Gerasimos Aravantinos; George Fountzilas; Aristotelis Bamias; Irene Grimani; Spy 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Southwest Oncology Group Trial S9912: In

Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer

✍ Harriet O. Smith; James Moon; Sharon P. Wilczynski; Amy D. Tiersten; Edward V. H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Moderately high-dose carboplatin with pa

Moderately high-dose carboplatin with paclitaxel and intraperitoneal cisplatin improves progression-free survival but has higher toxicity than standard intravenous cisplatin and paclitaxel for small volume ovarian cancer

✍ Mario De Lena 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Cost-effectiveness analysis of paclitaxe

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

✍ K. Berger; T. Fischer; T.D. Szucs 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Three-Hour Paclitaxel Infusion and Carbo

Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer

✍ John V. Brown; Mark A. Rettenmaier; Robert A. Dillman; Connie L. Birk; Kathleen 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 52 KB